An mRNA vaccine candidate against the human immunodeficiency virus, developed by the National Institute of Allergy and Infectious Diseases, Moderna and other institutes, shows a 79% efficacy rate and no major side effects in animal trials on rhesus macaques, according to a peer-reviewed paper published in Nature Medicine.